Home › Companies › KalVista Pharmaceuticals, Inc. › 2024-2025

KalVista Pharmaceuticals, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and KalVista Pharmaceuticals, Inc.’s Form 8-K, filed 2024-10-04 (Item 5.07 on EDGAR). Page generated 02 October 2026.

5Ballot items
142Asset managers
628Fund votes
2024-10-03Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KalVista Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by KalVista Pharmaceuticals, Inc.

These tallies are KalVista Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-10-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KalVista Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2024-10-03
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: William Fairey	30,169,349	872,398	33,171	--	8,328,823	Majority: yes
Elect Director: Nancy Stuart	19,324,277	11,717,484	33,157	--	8,328,823	Majority: yes
Proposal 2: Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending April 30, 2025:	39,323,443	46,858	33,440	--	0	Majority: yes
Proposal 3: Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers:	26,578,805	4,459,363	36,750	--	8,328,823	Majority: yes

Source: KalVista Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2024-10-04 — read the filing on EDGAR.

How asset managers voted at the KalVista Pharmaceuticals, Inc. 2024-2025 meeting

Each item below shows how the 142 asset managers that disclosed a KalVista Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2024-10-03.

Combines 6 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%AGAINST 14%

FOR: 26,578,805AGAINST: 4,459,363

KalVista Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers:”): 26,578,805 for, 4,459,363 against, per its Form 8-K filed 2024-10-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,215,472 outstanding shares: 62% for, 10% against (72% of the company cast a for/against vote).

The 138 asset managers below cast 77% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 77%AGAINST 23%

FOR: 76.9%AGAINST: 23.0%ABSTAIN: 0.1%

Largest asset managers voting on “Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as d” at KalVista Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
VR Adviser, LLC	6,249,731	0	For
Capital Group	282	6,062,990	Against
SUVRETTA CAPITAL MANAGEMENT, LLC	3,609,237	0	For
Vanguard	2,010,185	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	1,800,000	0	For
Vestal Point Capital, LP	1,595,397	0	For
BlackRock	1,323,894	18,352	For
GREAT POINT PARTNERS LLC	1,290,379	0	For
MPM BioImpact LLC	905,624	0	For
DAFNA Capital Management LLC	723,678	0	For
PERCEPTIVE ADVISORS LLC	500,000	0	For
EMERALD MUTUAL FUND ADVISERS TRUST	462,432	0	For
State Street	450,630	0	For
SILVERARC CAPITAL MANAGEMENT, LLC	380,129	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	344,734	0	For
EMERALD ADVISERS, LLC	336,786	0	For
FINANCIAL INVESTORS TRUST	278,261	0	For
Russell Investments	0	235,858	Against
Charles Schwab	221,440	0	For
Northern Trust	209,905	0	For
Nicholas Investment Partners, LP	0	190,129	Against
Principal	184,171	0	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	116,068	0	For
Woodline Partners LP	110,950	0	For
UBS	103,201	4,433	For

Showing the 25 largest of 138 asset managers. See all 138 in the interactive database.

2. The election of two Class III directors to hold office until the earliest of our 2027 annual meeting of stockholders and such individual's death, resignation or removal and the election and qualification of his or her successor: NANCY STUART

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-10-03.

Combines 6 wordings of this item as funds reported it.

62% Majority: yes · of votes cast

FOR 62%AGAINST 38%

FOR: 19,324,277AGAINST: 11,717,484

KalVista Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Nancy Stuart”): 19,324,277 for, 11,717,484 against, per its Form 8-K filed 2024-10-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,215,472 outstanding shares: 45% for, 27% against (72% of the company cast a for/against vote).

The 42 asset managers below cast 85% of the shares they voted on this item FOR (5,556,918 for, 995,376 against).

FOR 85%AGAINST 15%

FOR: 5,556,918 (84.8%)AGAINST: 995,376 (15.2%)

Largest asset managers voting on “The election of two Class III directors to hold office until the earliest of our 2027 annual meeting of stockh” at KalVista Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
Capital Group	3,031,495	0	For
Vanguard	1,927,903	0	For
BlackRock	353,147	0	For
FINANCIAL INVESTORS TRUST	0	278,261	Against
Principal	0	184,171	Against
Charles Schwab	0	110,720	Against
Russell Investments	100,174	0	For
DRIEHAUS MUTUAL FUNDS	0	74,868	Against
Advisors' Inner Circle Fund III	111	57,520	Against
Equitable	14,989	42,450	Against
Northern Trust	49,514	0	For
RBB FUND, INC.	0	39,035	Against
QUANTITATIVE MASTER SERIES LLC	33,117	0	For
Lincoln Financial	0	30,945	Against
Brinker Capital Destinations Trust	0	25,783	Against
Fidelity	24,016	0	For
Global X	0	20,995	Against
Dimensional	0	18,820	Against
John Hancock	0	14,851	Against
Pacific Life	13,504	0	For
American Century	0	13,095	Against
Brighthouse	0	12,559	Against
FORUM FUNDS II	0	11,509	Against
Jackson National	0	8,893	Against
ProShares	0	8,067	Against

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

3. The election of two Class III directors to hold office until the earliest of our 2027 annual meeting of stockholders and such individual's death, resignation or removal and the election and qualification of his or her successor: WILLIAM FAIREY

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-10-03.

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 30,169,349AGAINST: 872,398

KalVista Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: William Fairey”): 30,169,349 for, 872,398 against, per its Form 8-K filed 2024-10-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,215,472 outstanding shares: 70% for, 2% against (72% of the company cast a for/against vote).

The 42 asset managers below cast 93% of the shares they voted on this item FOR (6,084,751 for, 467,543 against).

FOR 93%7%

FOR: 6,084,751 (92.9%)AGAINST: 467,543 (7.1%)

Largest asset managers voting on “The election of two Class III directors to hold office until the earliest of our 2027 annual meeting of stockh” at KalVista Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
Capital Group	3,031,495	0	For
Vanguard	1,927,903	0	For
BlackRock	353,147	0	For
FINANCIAL INVESTORS TRUST	0	278,261	Against
Principal	0	184,171	Against
Charles Schwab	110,720	0	For
Russell Investments	100,174	0	For
DRIEHAUS MUTUAL FUNDS	74,868	0	For
Advisors' Inner Circle Fund III	57,631	0	For
Equitable	57,439	0	For
Northern Trust	49,514	0	For
RBB FUND, INC.	39,035	0	For
QUANTITATIVE MASTER SERIES LLC	33,117	0	For
Lincoln Financial	30,945	0	For
Brinker Capital Destinations Trust	25,783	0	For
Fidelity	24,016	0	For
Global X	20,995	0	For
Dimensional	18,820	0	For
John Hancock	14,851	0	For
Pacific Life	13,504	0	For
American Century	13,095	0	For
Brighthouse	12,559	0	For
FORUM FUNDS II	11,509	0	For
Jackson National	8,893	0	For
ProShares	8,067	0	For

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

4. THE RATIFICATION OF THE SELECTION, BY THE AUDIT COMMITTEE OF OUR BOARD, OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING APRIL 30, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2024-10-03.

Combines 2 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 39,323,443AGAINST: 46,858

KalVista Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending April 30, 2025:”): 39,323,443 for, 46,858 against, per its Form 8-K filed 2024-10-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,215,472 outstanding shares: 91% for, 0.2% against (91% of the company cast a for/against vote).

The 42 asset managers below cast 99.9% of the shares they voted on this item FOR (6,552,183 for, 111 against).

FOR 99.9%

FOR: 6,552,183 (100.0%)AGAINST: 111 (0.0%)

Largest asset managers voting on “THE RATIFICATION OF THE SELECTION, BY THE AUDIT COMMITTEE OF OUR BOARD, OF DELOITTE & TOUCHE LLP AS OUR INDEPE” at KalVista Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
Capital Group	3,031,495	0	For
Vanguard	1,927,903	0	For
BlackRock	353,147	0	For
FINANCIAL INVESTORS TRUST	278,261	0	For
Principal	184,171	0	For
Charles Schwab	110,720	0	For
Russell Investments	100,174	0	For
DRIEHAUS MUTUAL FUNDS	74,868	0	For
Advisors' Inner Circle Fund III	57,520	111	For
Equitable	57,439	0	For
Northern Trust	49,514	0	For
RBB FUND, INC.	39,035	0	For
QUANTITATIVE MASTER SERIES LLC	33,117	0	For
Lincoln Financial	30,945	0	For
Brinker Capital Destinations Trust	25,783	0	For
Fidelity	24,016	0	For
Global X	20,995	0	For
Dimensional	18,820	0	For
John Hancock	14,851	0	For
Pacific Life	13,504	0	For
American Century	13,095	0	For
Brighthouse	12,559	0	For
FORUM FUNDS II	11,509	0	For
Jackson National	8,893	0	For
ProShares	8,067	0	For

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

5. Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2023-09-26 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 20,001,348AGAINST: 2,652,134

KalVista Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers:”): 20,001,348 for, 2,652,134 against, per its Form 8-K filed 2023-09-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,215,472 outstanding shares: 46.3% for, 6% against (52.4% of the company cast a for/against vote).

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 405 against).

AGAINST 100%

AGAINST: 405 (100.0%)

Largest asset managers voting on “Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as d” at KalVista Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
COLDSTREAM CAPITAL MANAGEMENT INC	0	405	0	0	Against
Echo45 Advisors LLC	0	0	0	0	--

Largest KalVista Pharmaceuticals, Inc. shareholders voting in 2024-2025

Ranked by the number of KalVista Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 43,215,472 shares outstanding at the time of that meeting.

Top KalVista Pharmaceuticals, Inc. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	VR Adviser, LLC	14.46%
2	Capital Group	14.03%
3	SUVRETTA CAPITAL MANAGEMENT, LLC	8.35%
4	Vanguard	4.65%
5	ADAGE CAPITAL PARTNERS GP, L.L.C.	4.17%
6	Vestal Point Capital, LP	3.69%
7	BlackRock	3.11%
8	GREAT POINT PARTNERS LLC	2.99%
9	MPM BioImpact LLC	2.10%
10	DAFNA Capital Management LLC	1.67%

Reported KalVista Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

KalVista Pharmaceuticals, Inc. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Entities affiliated with Venrock Healthcare Capital Partners III, L.P.	11.60%	DEF14A
Venrock Healthcare Capital Partners III, L.P.	11.60%	13G
TANG CAPITAL MANAGEMENT, LLC	11.44%	13G
Tang Capital Partners, LP	11.44%	DEF14A
Entities affiliated with Frazier Life Sciences Public Fund, L.P.	11.31%	DEF14A
Entities affiliated with Suvretta Capital Management, LLC	10.02%	DEF14A
Capital World Investors	7.35%	13G
BlackRock	7.29%	13F
SilverArc Capital Management, LLC	6.66%	13G
Vanguard Group	5.32%	13F

Percentages above are of 43,215,472 shares outstanding, as reported by KalVista Pharmaceuticals, Inc. on its Form 10-Q dated 2024-08-26 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KalVista Pharmaceuticals, Inc.’s 10-Q dated 2024-08-26. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At KalVista Pharmaceuticals, Inc.'s shareholder meeting held 2024-10-03, in the 2024-2025 proxy season, 142 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 628 separate fund positions. On the most widely held item on that ballot — Approval, on a non-binding advisory basis, of the compensation paid by us to our named… — FOR was 86% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: KalVista Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-10-04.

KalVista Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.